Assessment of clinical usefulness of Procalcitonin (PCT) measurement in pneumonia patients
Not Applicable
- Conditions
- community-acquired pneumonia, hospital-acquired pneumonia, healthcare-associated pneumonia
- Registration Number
- JPRN-UMIN000003368
- Lead Sponsor
- agasaki evaluation organization for clinical interventions
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 300
Inclusion Criteria
Not provided
Exclusion Criteria
1) Patients already administered antibacterial agents for pneumonia before sample collection 2) Other patients judged to be inappropriate by the attending physician
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1) Assessment of relation between severity and PCT values in each CAP, HAP and HCAP. As indicators of severity, A-DROP and PSI systems are used for CAP, IROAD and PSI systems for HAP and A-DROP, IROAD and PSI systems for HCAP patients. 2) Assessment of relation between currently available inflammatory markers and PCT values in each CAP, HAP and HCAP patients. Inflammatory markers used as comparators: CRP, white blood cell count (WBC) 3) Assessment of relation between patient prognosis and PCT values in each CAP, HAP and HCAP patients. 4) Assessment of relation between causative pathogens and PCT values in each ach CAP, HAP and HCAP patients. 5) Examination of current status and profiles of HCAP. Differences between HCAP and CAP or HCAP will be compared in patient characteristics, laboratory findings and agents for initial treatment.
- Secondary Outcome Measures
Name Time Method